1. Home
  2. KBDC vs SPTX Comparison

KBDC vs SPTX Comparison

Compare KBDC & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

SELL

Current Price

$12.35

Market Cap

822.8M

Sector

N/A

ML Signal

SELL

Logo Seaport Therapeutics Inc. Common Stock

SPTX

Seaport Therapeutics Inc. Common Stock

HOLD

Current Price

$16.69

Market Cap

929.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBDC
SPTX
Founded
2021
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
822.8M
929.8M
IPO Year
2018
2026

Fundamental Metrics

Financial Performance
Metric
KBDC
SPTX
Price
$12.35
$16.69
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$14.50
★ $38.29
AVG Volume (30 Days)
★ 383.0K
272.3K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 12.85%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.85
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.65
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.32
$16.03
52 Week High
$15.87
$28.38

Technical Indicators

Market Signals
Indicator
KBDC
SPTX
Relative Strength Index (RSI) 31.50 35.45
Support Level N/A N/A
Resistance Level $14.20 $22.75
Average True Range (ATR) 0.22 1.49
MACD -0.02 -0.22
Stochastic Oscillator 3.08 14.27

Price Performance

Historical Comparison
KBDC
SPTX

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.

About SPTX Seaport Therapeutics Inc. Common Stock

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

Share on Social Networks: